BIOLASE to Showcase Two New Game-Changing Products at International Dental Show in Cologne

Download as PDF

Minimally Invasive Waterlase Express™ All-Tissue Laser and Epic Pro™ Soft-Tissue Laser Expand Portfolio of Lasers for Every Dentist

IRVINE, Calif. & COLOGNE, Germany--(BUSINESS WIRE)-- BIOLASE, Inc., (NASDAQ: BIOL) the global leader in dental lasers, announced today that it would showcase its two new, game-changing, minimally invasive dental lasers, the Waterlase Express all-tissue laser and the Epic Pro soft-tissue diode laser, at the 37th International Dental Show (IDS) March 21-25 in Cologne, Germany. The show, the world’s largest dental meeting with 2,300 exhibitors from 60 countries, is expected to draw more than 140,000 visitors. IDS is known for its presentations of the latest products, developments and trends in the global dental industry.

The Waterlase Express features the Company’s fifth generation laser technology and represents the new foundation of the Company’s strategy to greatly expand all-tissue laser use in dentistry. It is the industry’s smallest, easiest to use most technologically advanced, customer supportive and affordable dental all-tissue laser system. It was designed with simple, elegant user controls and learning tools so that every dentist, even those new to lasers, can easily learn its capabilities.

The Epic Pro, the first commercially available laser system created in collaboration with IPG Medical Corporation, is the Company’s premium diode laser solution and is unlike anything else on the market. It offers advancements in power, cutting speed, control and precision and allows BIOLASE to access new segments of the market it has not penetrated, including oral and maxillofacial surgery.

BIOLASE President and CEO Harold C. Flynn, Jr. and Holger Arens, the new Vice President and Managing Director for Europe, the Middle East and Africa (EMEA) who is based in Germany, will be among the Company’s executives attending the show and meeting with key distributors and clinicians.

“We believe the international dental market—and in particular Europe and the Middle East, the largest single geographic region in dentistry—represents a tremendous, untapped opportunity for laser dentistry,” Flynn said. “With our two new innovative products now being sold in the US and select international markets, and Holger on the ground building a much stronger and broader presence, we are confident we can reach an entirely new level of market penetration. We are offering the industry a glimpse of dentistry of the future and this conference is an excellent place to showcase our products and the progress we have made as a company. We believe with the addition of these two ground breaking products, we now have lasers for every dentist and that laser dentistry will become the standard of care in modern dentistry.”

BIOLASE will be located in the following stands: German/Intl. Pavilion, Hall 11.3, Stand E050 and US Pavilion, Hall 04.2, Stand L060 M061. Visitors will see a fully interactive exhibition and display, hands-on demonstrations of the laser system portfolio and guest speakers.

To learn more about the Waterlase Express system, the Epic Pro, and other innovations designed to simplify laser dentistry, visit www.biolase.com.

About BIOLASE, Inc.

BIOLASE, Inc. is a medical device company that develops, manufactures, markets, and sells laser systems in dentistry and medicine and also markets, sells, and distributes dental imaging equipment, including digital x-rays and CAD/CAM scanners. BIOLASE’s products are focused on technologies that advance the practice of dentistry to both dentists and their patients. BIOLASE's proprietary laser products incorporate approximately 230 patented and 85 patent-pending technologies designed to provide biologically clinically superior performance with less pain and faster recovery times. BIOLASE’s innovative products provide cutting-edge technology at competitive prices to deliver the best results for dentists and patients. BIOLASE's principal products are revolutionary dental laser systems that perform a broad range of dental procedures, including cosmetic and complex surgical applications, and a full line of dental imaging equipment. BIOLASE has sold approximately 33,600 laser systems to date in over 90 countries around the world. Laser products under development address BIOLASE’s core dental market and other adjacent medical and consumer markets.

For updates and information on Waterlase® iPlus™ and laser dentistry, find BIOLASE online at www.biolase.com, Facebook at www.facebook.com/biolase, Twitter at www.twitter.com/biolaseinc, LinkedIn at www.linkedin.com/company/biolase, Instagram at www.instagram.com/biolaseinc, and YouTube at www.youtube.com/biolasevideos.

BIOLASE® and Waterlase® are registered trademarks of BIOLASE, Inc.

Safe Harbor Statement under the Private Securities Litigation Reform Act of 1995

Statements contained in this press release that refer to BIOLASE's estimated or anticipated future results or other non-historical facts are forward-looking statements, as are any statements in this press release concerning prospects related to BIOLASE's strategic initiatives and anticipated financial performance. Forward-looking statements can also be identified through the use of words such as “anticipates,” “expects,” “intends,” “plans,” “believes,” “seeks,” “estimates,” “may,” “will,” and variations of these words or similar expressions. Readers are cautioned not to place undue reliance on these forward-looking statements, which reflect BIOLASE's current expectations regarding existing trends, and its strategic initiatives, and speak only as of the date of this release. Actual results may differ materially from BIOLASE’s current expectations depending upon a number of factors affecting BIOLASE’s business. These factors include, among others, adverse changes in general economic and market conditions, competitive factors including but not limited to pricing pressures and new product introductions, uncertainty of customer acceptance of new product offerings and market changes, risks associated with managing the growth of the business, and those other risks and uncertainties that may be detailed, from time-to-time, in BIOLASE's reports filed with the SEC. BIOLASE does not undertake any responsibility to revise or update any forward-looking statements contained herein.

BIOLASE
Michael Roux, 949-226-8112
Vice President of Marketing
mroux@biolase.com
or
DresnerAllenCaron
Michael Mason, 212-691-8087
(Investors)
mmason@dresnerallencaron.com
or
Rene Caron
(Investors)
rcaron@dresnerallencaron.com
or
Len Hall, 949-474-4300
(Media)
lhall@dresnerallencaron.com

Source: BIOLASE

Released March 20, 2017